Through our proprietary research platform, RXcel has identified a well-defined molecular driver in glioblastoma. This target offers a rational and potentially transformative approach to treatment, setting the foundation for a more precise therapeutic intervention.
Despite current standard-of-care treatments (surgery, radiotherapy, and temozolomide), median survival for patients with glioblastoma remains just 12 to 15 months. There have been few advances over the past two decades, and recurrence is almost inevitable. Novel, targeted therapies are urgently needed.
Compared to other solid tumors, glioblastoma sees disproportionately low clinical trial activity — despite its severity and poor prognosis. This highlights a major gap in innovation and investment that RXcel is aiming to address.